EA202090431A1 - INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT - Google Patents
INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENTInfo
- Publication number
- EA202090431A1 EA202090431A1 EA202090431A EA202090431A EA202090431A1 EA 202090431 A1 EA202090431 A1 EA 202090431A1 EA 202090431 A EA202090431 A EA 202090431A EA 202090431 A EA202090431 A EA 202090431A EA 202090431 A1 EA202090431 A1 EA 202090431A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- muteins
- interleukin
- treatment
- fusion proteins
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
В изобретении предусмотрены мутеины IL-21 и слитые белки, содержащие их, для применения в способах лечения заболевания. Также в изобретении предусмотрены соответствующие конъюгаты, нуклеиновые кислоты, векторы, клетки-хозяева, фармацевтические композиции и наборы. В настоящем изобретении предусмотрены способы получения мутеинов IL-21 и слитых белков, содержащих их, а также способы лечения субъекта, нуждающегося в этом. Дополнительно предусмотрены антигенсвязывающие белки для PD-1.The invention provides IL-21 muteins and fusion proteins containing them for use in methods of treating disease. Also provided by the invention are appropriate conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions, and kits. The present invention provides methods for producing IL-21 muteins and fusion proteins containing them, as well as methods for treating a subject in need thereof. Additionally, antigen binding proteins for PD-1 are provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862616733P | 2018-01-12 | 2018-01-12 | |
PCT/US2018/045105 WO2019028316A1 (en) | 2017-08-03 | 2018-08-03 | Interleukin-21 muteins and methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090431A1 true EA202090431A1 (en) | 2021-03-16 |
Family
ID=71842940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090431A EA202090431A1 (en) | 2018-01-12 | 2018-08-03 | INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR114079A1 (en) |
EA (1) | EA202090431A1 (en) |
-
2018
- 2018-08-03 EA EA202090431A patent/EA202090431A1/en unknown
-
2019
- 2019-01-11 AR ARP190100060A patent/AR114079A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR114079A1 (en) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125429T1 (en) | INTERLEUKIN-21 MUTEINS AND METHODS OF THERAPEUTIC TREATMENT | |
EA202091710A1 (en) | ANTIBODIES AGAINST CD73 AND METHODS OF THEIR USE | |
UY38049A (en) | ANTI-PD-1 ANTIBODIES AND TREATMENT METHODS | |
CO2018012415A2 (en) | Specific binding proteins and uses thereof | |
CY1119647T1 (en) | ALUMINUM ACCESSORIES AND ACCESSORIES FOR ACCESSORIES | |
CY1119219T1 (en) | ANTI-CEACAM5 ANTIBODIES AND THEIR USES | |
EA201991383A1 (en) | ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION | |
EA201892616A1 (en) | ANTIBODIES TO PD1 AND LAG3 FOR THE TREATMENT OF MALIGNANT NUMER FORMATION | |
PE20200148A1 (en) | ANTI-TREM2 ANTIBODIES AND METHODS TO USE THEM | |
EA202092735A1 (en) | ANTAGONIZING CD73 ANTIBODY | |
EA201590138A1 (en) | OPTIMIZATION OF ANTIBODIES THAT BIND THE ACTIVATION GENE OF LYMPHOCYTES 3 (LAG-3) AND THEIR USE | |
EA201991763A1 (en) | CCR7 ANTIBODY AND MEDICINE CONJUGATES | |
EA201892774A1 (en) | ANTIBODIES | |
EP4339615A3 (en) | Anti-pd-1 antibodies | |
CY1122436T1 (en) | ANTIBODIES AGAINST THE EPITANIAL GROWTH FACTOR RECEPTOR (EGFR) | |
EA202092459A1 (en) | INTERLEUKIN 12 HYBRID PROTEINS, COMPOSITIONS AND METHODS OF THERAPEUTIC APPLICATION, WHICH INCLUDE THEM | |
EA202090372A1 (en) | UNIVERSAL AVT CONNECTIONS AND THEIR APPLICATION | |
EA202090387A1 (en) | PROTEINS BINDING NKG2D, CD16 AND FLT3 | |
EA202190468A1 (en) | MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16 AND METHODS OF THEIR APPLICATION | |
EA201790489A1 (en) | THERAPEUTIC TOOLS BASED ON ANTIBODIES, BINDING OprF AND OprI | |
MX2021011330A (en) | Claudin-6 antibodies and drug conjugates. | |
EA202192488A1 (en) | ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS | |
EA202191658A1 (en) | ANTIBODIES AGAINST HUMAN COMPLETE FACTOR C2B AND METHODS OF APPLICATION | |
EA202090431A1 (en) | INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT | |
EA202091596A1 (en) | ANTIBODIES TO PD-1 AND METHODS OF TREATMENT |